Last reviewed · How we verify
broad area ALA 3-hour incubation
At a glance
| Generic name | broad area ALA 3-hour incubation |
|---|---|
| Also known as | Levulan |
| Sponsor | DUSA Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- broad area ALA 3-hour incubation CI brief — competitive landscape report
- broad area ALA 3-hour incubation updates RSS · CI watch RSS
- DUSA Pharmaceuticals, Inc. portfolio CI